Only Panorama® can distinguish between fetal and maternal DNA in the mother's blood to give you and your patient vital information about the fetus. With a comprehensive panel of chromosomal aneuploidies and microdeletions, Panorama® delivers the most accurate results of any screening test, as early as 9 weeks of gestation, to help you manage your patient's pregnancy.

Choose Panorama®

You and your patients deserve the reassurance that comes from using a prenatal screening test with the highest combined accuracy across a broad panel of genetic conditions.

Powered by the most advanced bioinformatics technology. the Panorama® test provides personalized risk scores for aneuploidy at chromosomes 13, 18, 21, X and Y, triploidy, and microdeletions with the highest combined accuracy in published clinical trials.

The benefits of Panorama® are VAST:

Vanishing Twin: Only Panorama® can distinguish if a vanishing twin's DNA is still present in maternal circulation. The presence of DNA from a vanishing twin cannot be detected using other NIPT methods and can result in an increase in false positive or false negative test results.

Analysis of the maternal contribution: Only Panorama® evaluates the maternal genotype in addition to the fetal genotype, thereby providing a clearer result on the pregnancy.

Triploidy: Only Panorama® can detect triploidy as well as provide a risk assessment on every report. This assessment can be beneficial when ultrasound findings are suggestive of triploidy, or for couples seeking recurrence risk assessment following a previous pregnancy with triploidy.

Panorama® builds on this technology to provide high sensitivity rates even at low fetal fraction.

The Most Accurate

Panorama® provides risk assessment on more clinically significant chromosome abnormalities than other NIPTs. Every Panorama® report includes a personalized risk score for trisomy 21, 18, 13, and monosomy X.

In addition, Panorama® offers a panel of microdeletion syndromes. These syndromes were chosen with care to provide relevant information for conditions that are common, can be severe, are under-diagnosed prenatally, and may benefit from early intervention after delivery.

Clinical Data

Panorama® demonstrates greater screening accuracy in many common chromosomal abnormalities, as well as fetal sex, compared to other NIPTs.

Fetal Fraction

Up to 1/3 of all NIPT cases have < 8% fetal fraction, which is often associated with decreased sensitivity. Panorama® measures fetal fraction and adjusts its algorithm accordingly to improve sensitivity even at low fetal fractions. We report fetal fraction for all cases, providing you reliable information as you counsel your patients.

Minimal False Negatives

Low fetal fraction is one of the most common causes of false negative results.

Panorama® has the lowest false negative rate, 0.7%, in published clinical trials.

For example, as women age, some of their cells begin to lose the X chromosome, as shown on the chart to the left. As a result, NIPT tests may incorrectly report Monosomy X because they detect a lower than expected amount of the X chromosome in maternal plasma. As the only NIPT test that distinguishes between fetal and maternal DNA, Panorama® accurately detects fetal chromosomal abnormalities, even in the presence of maternal mosaicism.

Comprehensive

What We Screen For

Triploidy

Microdeletions

22q11.2 Deletion Syndrome

1

2

3

Left

Right

1

2

3

4

Left

Right

1

2

3

Left

Right

How Panorama® works

Panorama® is the only non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera's proprietary algorithm.

Talk to your patients about Panorama®

Evidence supports the use of NIPT as the first line screen for all pregnancies, regardless of risk.